Plumb Pharmaceuticals specializes in extended release drug delivery systems utilizing liposome technology to enhance the stability and bioavailability of medications for chronic disease management. Their approach addresses the high healthcare costs associated with chronic conditions by improving drug efficacy and reducing the frequency of dosing.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current medications for chronic diseases often require frequent dosing, leading to issues with patient compliance, reduced drug efficacy, and increased healthcare costs. This is particularly problematic in conditions like opioid addiction, where relapse between doses can have severe consequences.
Solution
Plumb Pharmaceuticals is developing extended-release drug delivery systems based on its Advanced Quantload (AQL™) liposome technology. This platform enables the encapsulation of high concentrations of drugs within lipid nanoparticles, allowing for sustained release over months from a single subcutaneous injection. The AQL™ technology improves medication compliance, reduces the frequency of clinic visits, and enhances drug efficacy by maintaining therapeutic levels for extended periods. Plumb's lead product, AQL™-Nal, is a long-acting injectable naltrexone formulation for opioid use disorder designed to prevent relapse for up to six weeks, potentially exceeding the duration of existing treatments while minimizing injection pain and tissue damage.
Target Audience
The primary target audience includes healthcare providers and patients managing chronic diseases, particularly opioid use disorder, seeking improved medication adherence and reduced dosing frequency.
Features
- AQL™ platform technology for super extended-release of FDA-approved drugs
- Liposome-based drug delivery system for subcutaneous injection
- High drug encapsulation efficiency within lipid nanoparticles
- Sustained drug release over months, reducing dosing frequency
- AQL™-Nal: Extended-release naltrexone formulation for opioid use disorder
- Reduced injection pain and tissue damage compared to existing treatments
- Potential applications for mood stabilizers, pain control medications, and other chronic disease therapies
- Two issued patents for liposomal formation and indirect loading method